| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Scientific Officer | Officer Level 14 | EVP & Chief Scientific Officer +2 more
1 company
C Frank Bennett is EVP, Chief Scientific Officer at IONS. C Frank Bennett's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.4M at current prices.
Our model assigns C Frank Bennett a middling insider score of 64/100, based on 19 past trades. Over a 12-month horizon, 57.1% of those trades were profitable, with an average 12-month return of -8.5%.
The IONS filings lean toward selling, a net 389,651 shares.
C Frank Bennett has 52 Form 4 filings on record from January 2019 to August 2026, all as EVP, Chief Scientific Officer at Ionis Pharmaceuticals (IONS), 2019–2026.
The 101 reported transactions were 30 open-market sales, 24 option exercises, 21 option or other derivative awards and 18 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 22 sales worth about $26.2M.
The largest open-market sale was 85,089 shares of IONS at an average $82.93 on February 2, 2026, about $7.1M.
9 of the 15 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 6 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chief Scientific Officer | Sell10b5-1 | 20,536 | $84.95 | $1,744,623.34 | -100% | -49.6% | - | |
| Mar 3, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chief Scientific Officer | Sale+OE10b5-1 | 85,089 | $79.23 | $6,741,669.17 | -51.4% | -4.2% | - | |
| Feb 2, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chief Scientific Officer | Sale+OE10b5-1 | 85,089 | $82.93 | $7,056,215.53 | -51.4% | -9.2% | - | |
| Jan 30, 2026 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Scientific Officer | Sell | 5,885 | $82.95 | $488,140.74 | -5.5% | -9.6% | - | |
| Jan 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Chief Scientific Officer | Sale+OE | 8,977 | $75.15 | $674,621.55 | -8.7% | -1.4% | - | |
| Sep 5, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Scientific Officer | Sell10b5-1 | 6,000 | $59.60 | $357,580.80 | -6.8% | +33.6% | -5.1% | |
| Sep 3, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Scientific Officer | Sale+OE10b5-1 | 38,909 | $59.14 | $2,301,263.58 | -27.7% | +34.4% | -3.9% | |
| Aug 18, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Scientific Officer | Sale+OE10b5-1 | 10,000 | $43.98 | $439,776.00 | -9.7% | +68.7% | +37.3% | |
| Jan 31, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Scientific Officer | Sell | 1,327 | $32.46 | $43,079.20 | -1.4% | -0.6% | +159.2% | |
| Jan 16, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Scientific Officer | Sale+OE | 6,752 | $32.90 | $222,113.79 | -6.9% | -12.2% | +136.5% |